Information Provided By: 
Fly News Breaks for August 7, 2018
SAGE
Aug 7, 2018 | 12:03 EDT
Sage Therapeutics continues to make progress preparing for potential FDA approval/launch of Zulresso for post partum depression, Piper Jaffray analyst Danielle Brill tells investors in a research note following the company's Q2 results. The analyst expects the FDA panel on November 2 to be supportive of approval. She reiterates an Overweight rating on Sage shares with a $206 price target.
News For SAGE From the Last 2 Days
